Agios Pharmaceuticals Inc... (AGIO)
30.28
-0.56 (-1.82%)
At close: Mar 28, 2025, 3:59 PM
29.30
-3.25%
After-hours: Mar 28, 2025, 06:25 PM EDT
Agios Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | 36.5M | 26.82M | 14.24M | n/a | 203.2M | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M | 25.55M | 25.11M | 21.84M |
| Cost of Revenue | 4.17M | 9.5M | 1.7M | 18.78M | 2.81M | 1.32M | 1.4M | 292.68M | 220.16M | 141.83M | 100.37M | 54.5M | 41.04M | n/a |
| Gross Profit | 32.33M | 17.32M | 12.54M | -18.78M | 200.39M | 116.59M | 92.99M | -249.67M | -150.27M | -82.71M | -35.01M | -28.95M | -15.93M | 21.84M |
| Operating Income | -425.74M | -391.49M | -389.05M | -378.42M | -316.15M | -426.33M | -362.48M | -320.79M | -200.99M | -118.7M | -54.13M | -38.88M | -23M | -16.63M |
| Interest Income | 48.08M | 33.34M | 12.79M | 836K | 6.61M | 14.86M | 16.45M | 6.12M | 2.51M | 968K | 203K | 55K | 69K | 132K |
| Pretax Income | 717.97M | -352.09M | -231.8M | -356.51M | -327.37M | -411.47M | -346.03M | -314.67M | -198.47M | -117.73M | -53.93M | -38.83M | -22.93M | -16.5M |
| Net Income | 673.73M | -352.09M | -74.56M | 1.6B | -335.22M | -396.61M | -346.03M | -314.67M | -198.47M | -117.73M | -53.5M | -39.41M | -20.1M | -23.71M |
| Selling & General & Admin | 156.78M | 119.9M | 121.67M | 121.44M | 149.07M | 132.03M | 114.14M | 71.12M | 50.71M | 35.99M | 19.12M | 9.93M | 7.06M | 7.21M |
| Research & Development | 301.29M | 288.9M | 279.91M | 256.97M | 367.47M | 410.89M | 341.32M | 292.68M | 220.16M | 141.83M | 100.37M | 54.5M | 41.04M | 31.25M |
| Other Expenses | n/a | n/a | 6.75M | 14.43M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 458.07M | 408.81M | 401.58M | 378.42M | 516.54M | 542.93M | 455.47M | 363.81M | 270.88M | 177.82M | 119.49M | 64.43M | 48.1M | 38.47M |
| Interest Expense | n/a | n/a | 12.79M | n/a | 17.83M | n/a | 16.45M | 6.12M | 2.51M | 968K | 203K | 55K | 69K | 132K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 462.24M | 418.31M | 403.29M | 378.42M | 519.35M | 544.25M | 456.87M | 363.81M | 270.88M | 177.82M | 119.49M | 64.43M | 48.1M | 38.47M |
| Income Tax | 44.24M | n/a | -157.25M | -1.98B | 7.85M | -14.86M | 32.9M | -6.43M | -5.71M | -426K | -426K | 579K | -2.82M | 7.21M |
| Shares Outstanding (Basic) | 56.81M | 55.65M | 54.79M | 60.45M | 69M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.41M | 23.39M | 23.39M |
| Shares Outstanding (Diluted) | 57.89M | 55.65M | 54.79M | 60.45M | 69M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.41M | 23.39M | 23.39M |
| EPS (Basic) | 11.86 | -6.33 | -1.36 | 26.55 | -4.86 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.56 | -0.86 | -1.01 |
| EPS (Diluted) | 11.64 | -6.33 | -1.36 | 26.55 | -4.86 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.56 | -0.86 | -1.01 |
| EBITDA | -425.74M | -384.86M | -380.48M | -337.73M | -326.13M | -394.85M | -338.86M | -314.36M | -195.28M | -115.36M | -52.77M | -37.44M | -21.82M | -15.83M |
| Depreciation & Amortization | n/a | 6.62M | 18.56M | 18.78M | 18.77M | 16.62M | 7.17M | 6.43M | 5.71M | 3.34M | 1.37M | 1.44M | 1.18M | 801K |